Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
Quince is an affordable luxury brand that sells high-quality fashion and home goods at low prices through direct sales from the factory. The company uses a manufacturer-to-consumer (M2C) retail model, where factories produce inventory on a near just-in-time basis. This model allows Quince to ship products directly to consumers, minimizing financial and environmental waste.
AMP is an AI technology company that modernizes recycling infrastructure through smart sortation solutions. The company focuses on maximizing resource recovery while minimizing labor costs for waste management operations. With numerous deployments globally, AMP aims to transform the economics of recycling.
Saluda Medical is a commercial-stage medical device company that develops treatments for chronic neurological conditions using a novel closed-loop, dose-control neuromodulation platform. Its novel neuromodulation platform is designed to sense and measure neural responses to stimulation and automatically adjust therapy based on real-time neurophysiological feedback.
Meati Foods is a consumer goods company that provides fungi-based meat alternatives to everyone. It focuses on using proprietary, clean technologies to provide nutrient-dense, plant-based meat alternatives that everyone can enjoy and feel good about eating every day. Meati Foods was founded in 2016 and is headquartered in Boulder, United States.
Moving Analytics is a telehealth service provider that specializes in cardiovascular prevention programs. Its first product Movn is an end-to-end, integrated program to deliver remote and virtual cardiac rehab. The platform reduces readmissions and empowers the effective and efficient delivery of quality care to patients based on 30+ years of research in remote disease management from Stanford University.
FalconX is a cryptocurrency brokerage and digital asset trading platform. It specializes in the fields of blockchain, cryptocurrency, and fintech. Its platform provides reliable execution using data science to eliminate slippage and hidden fees. It was founded in 2018 and is based in San Mateo, California.
Arcadia is a climate crisis-fighting technology company founded in 2014 and born out of a simple idea—everyone deserves access to clean energy. Arcadia breaks the fossil fuel monopoly by creating unprecedented access to energy data and renewable energy sources through its technology platform, Arc, and its community solar program. Arc fuels the renewable energy revolution by democratizing access to energy data from 125 utilities nationwide, covering more than 80% of US electric utility accounts. Arcadia also manages the nation’s leading community solar program, helping to tackle energy injustice while spurring economic growth with more than five Terawatt-hours of residential and commercial energy demand.
Span.IO develops products to enable the rapid adoption of renewable energy and deliver an intuitive interface for the home. They are a group of engineers with a passion for building products that can deliver a positive impact on the environment while enhancing the consumer experience. They believe that developing intelligent hardware and software that provides visibility and control at the edge of the grid will be transformational to the energy sector. The company is backed by domain experts in energy, software, hardware, and consumer finance. They leverage their teams' collective experience in power generation, energy conversion, controls, and system integration to develop core products focused on enabling the rapid adoption of renewable energy.
Omada Health is a digital care company that offers innovative and clinically effective digital health programs to empower individuals to engage in their health and lead healthier lives. The program is personalized to meet each participant’s unique needs as they evolve, ranging from diabetes prevention, type 2 diabetes management, hypertension, behavioral health, and musculoskeletal issues. Omada combines professional health coaching, connected health devices, real-time data, and personalized feedback to deliver clinically meaningful results. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program.
Somatus is a healthcare company that partners with health plans, health systems, nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia and is founded by a team of healthcare operators, entrepreneurs, and clinicians who treat kidney disease.
Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. The company was founded in 2012 and is based in Redwood City, California.
CodeSee is a developer of cloud-based data visualization software to help everyone master the understanding of code. Its software delivers the tools to continuously understand the codebase at every step of the development process, helping developers and development teams to understand how all of the code and functionality map to each other. The company was founded in 2019 and is based in San Francisco, California.
Dave is disrupting the banking business with its innovative financial products. Dave products improve its members' financial wellness by offering banking with no hidden costs, free access to a $250 overdraft, credit building, and access to extra side business options. In less than four years, the company has grown to over 12 million members, making it one of the fastest-growing financial apps ever. Dave, the financial equivalent of David and Goliath battling the big banks, assists its 12 million customers in budgeting, finding work, building credit, and accessing revenue to fund current expenditures. Dave is intended to fill in for a friend or family member who you turn to for instant money or financial advice.
Taqanal Energy is powering the shift from fossil fuels and internal combustion engines through its Intelligent Energy Storage Management System which integrates the power of embedded intelligence in the battery with cloud applications.
ROKT is a software development company that offers e-commerce technology and software solutions to introduce marketing into e-commerce through the transaction moment in order to revolutionize the consumer purchasing experience. The business links consumers and marketers and integrates native advertisements into e-commerce sites' transactional flows.
Olist is an SMB commerce enabler ecosystem that specializes in the fields of logistics and capital. Commerce has changed and platforms like shopify, amazon, meli, alibaba and their peers are more and more relevant to our economy throughout the globe. This movement triggered a new generation of enablers to support small businesses navigate in such rich and fragmented ecosystem. Olist is leading the way as the #1 commerce enabler for SMBs in Brazil, now expanding globally. The company started with a single core connecting merchants to marketplaces and evolved to a complete ecosystem of integrated products in 3 dimensions. (1) Commerce: (a) Olist Store is the leading solution to sell on marketplaces; (b) Olist Shops is our ecommerce solution, mobile first, natively connected to social media, present in 180 countries. (2) Logistics: Olist Pax is a leading cloud based logistics and fulfillment network provider operating in Brazil. (3) Capital: Olist Credit and Olist Pay.
Learneo brands and platforms are pioneering advances in a wide range of applications for emergent technologies, including the use of AI to improve people's writing, reading and math skills, in school, professional and daily life. The platform of businesses includes CliffsNotes, the original and iconic study guide company; Course Hero, an online learning platform of academic resources; LitCharts, a creator of literature resources; QuillBot, an AI-powered writing companion helping anyone improve their writing skills; Scribbr, a multilingual academic proofreading service, and Symbolab, an AI-based mathematics resource. Learneo was established in Redwood City, California by Andrew Grauer and Gregor Carrigan.
Chroma Medicine is a new genomic medicine company working on epigenetic editing. Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize the treatment of genetically driven diseases. Chroma Medicine was established in 2021 in Cambridge, Massachusetts.
Faire is a two-sided marketplace and wholesale platform that helps retailers find and buy unique wholesale merchandise for their stores while helping brands and makers reach local retailers. Faire offers business owners a toolkit of simple tech, data insights, financial terms, and logistics solutions to support the future of local retail. Faire's net 60 payment terms and free returns take the risk out of the wholesale business so that local retailers and independent brands can compete with big-box and ecommerce giants. Faire is headquartered in San Francisco, California, United States, and Kitchener, Ontario, Canada.
Teya is an all-in-one solution for small and growing businesses. From payments, to loyalty, to the cash advance merchants use to give their shops that facelift – Teya has helped over 300,000 business owners to connect with the joy of running their business.
BetterUp is a human transformation company that dares to innovate the future of work by helping people and businesses grow personally and professionally to reach peak performance and maximize their potential, through coaching, content, community, and cutting-edge AI technology. BetterUp is the inventor of virtual coaching and the largest mental health and coaching startup in the world, with the world’s largest network of over 3,000 Coaches offering support in 46 languages across over 90 countries. Trusted by more than 380 organizations including NASA, Google, Snap Inc., Hilton, Warner Media, and other leading Fortune 1,000 companies, BetterUp delivers on three key impact areas – Mental Fitness, career & leadership development, and social connection – inspiring people everywhere to live with greater clarity, purpose, and passion. Investors include Wellington Management, ICONIQ Growth, Lightspeed Venture Partners, Threshold Ventures, PLUS Capital, Salesforce Ventures, Sapphire Ventures, Mubadala Investment Company, Morningside Group, SV Angel, Freestyle Capital, Crosslink Capital, and Tenaya Capital. BetterUp’s Science Board is composed of leading researchers in the fields of positive psychology and human performance including Martin Seligman, Adam Grant, Shawn Achor, and Quinetta Roberson. BetterUp has been recognized in the Inc. 5000, Fortune’s Great Places to Work, and People Magazine’s Companies that Care.
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Archaea Energy is a developer of renewable natural gas (“RNG”) which is a sustainable decarbonizing solution for high-carbon emission processes and industries that are impossible or inefficient to electrify. The company's goal is to capture waste emissions and turn them into low-carbon fuel, the RNG platform builds, operates, and maintains RNG facilities. Archaea Energy was established in 2018 by Nick Stork in Canonsburg, Pennsylvania.
Arcadia is a climate crisis-fighting technology company founded in 2014 and born out of a simple idea—everyone deserves access to clean energy. Arcadia breaks the fossil fuel monopoly by creating unprecedented access to energy data and renewable energy sources through its technology platform, Arc, and its community solar program. Arc fuels the renewable energy revolution by democratizing access to energy data from 125 utilities nationwide, covering more than 80% of US electric utility accounts. Arcadia also manages the nation’s leading community solar program, helping to tackle energy injustice while spurring economic growth with more than five Terawatt-hours of residential and commercial energy demand.
SpotOn’s mission is to give small and midsize businesses a fighting chance, providing innovative software and payment solutions, supported by local and personal service, and delivered at a fair price. A leader in fully integrated restaurant management systems and small business technology, SpotOn offers end-to-end solutions which include marketing, website development, reservations, online ordering, appointments, eCommerce, digital loyalty, review management, as well as retail and restaurant point-of-sale (POS) solutions. Doron Friedman, Matt Hyman, and Zach Hyman co-founded SpotOn in 2017 and its headquarters is located in San Francisco, California.
Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.
Trove AI, Inc. develops a mobile email application. The company develops artificial intelligence (AI) solutions that solve email overload and enhance communications. Its AI solution offers smart multi-swiping and email notifications; surfaces insights about user’s relationships; and lets snoozing emails to get them out of the user’s way until the user is ready to get to them. The application works with existing email services. Its mobile application is compatible with iOS and Android devices. The company was formerly known as Notion AI, Inc. Trove AI, Inc. was founded in 2013 and is based in Ann Arbor, Michigan.
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening to streamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology.
Lucid Motors is an automotive company that specializes in electric cars. The company sets out to create a car that elevates the human experience and transcends the perceived limitations of space, performance, and intelligence. A car that is intuitive, liberating, and designed for all the ways people get around. It was founded in 2007 and headquartered in Newark, California.
Keeping technology at the core, Blackbuck is redefining the logistics landscape of India, making it reliable and efficient. Blackbuck's comprehensive approach to problems creates impact on the entire ecosystem of transportation, which stitches across large number of livelihoods. The transportation sector is ripe for a revolution, and Blackbuck marks the beginning. Founded in 2015, BlackBuck has been a pioneer in bringing the offline operations of trucking online, be it matching a shipper with a trucker or reshaping the infrastructure around trucking to facilitate payments, insurance, and financial services. BlackBuck is committed to making it easier for millions of truckers to book a load and move at capacity and enable shippers of all sizes to have access to the right truck, at the right time for the right price – all at a click of a button. Today, BlackBuck is India’s largest trucking network, and the company’s robust technology platforms deliver reliability, efficiency and seamless experience for shippers and truckers. BlackBuck is powered by a 2000 strong incredible team and is supported by the best of investors’ fraternity that includes Accel Partners, Apoletto Asia, B Capital, Flipkart, Goldman Sachs, IFC, Light Street, Sands Capital, Sequoia Capital, Tiger Global and Wellington. BlackBuck has won ‘CNBC-TV18 - Young Turks Startup of the Year’ award and ‘Zee Business- Company of the year-Logistics’ award in 2018. BlackBuck is also the subject of a ‘Harvard Business School’ case study.
Swiggy is an on-demand food delivery platform that brings food from neighborhood restaurants directly to customers' doors. The company's food delivery platform lists local restaurants and menu lists on an app for users to order from and track the delivery of its delivery executives, enabling users to order food with speed and convenience. Its service is used to pick up and drop off a diverse array of items, including laundry and document or parcel deliveries to business clients and retail customers.
ironSource is a business platform enabling mobile content creators to prosper in the app economy. Our mission is to help app developers turn their apps into scalable and sustainable, with the most robust, comprehensive business platform available. Ultimately, we help customers focus on what they do best - creating great apps and user experiences - while we enable their business expansion in the app economy.
Payoneer is a financial technology company that enables small and medium-sized enterprises to transact and thrive.
As of October 16, 2020, FinTech Acquisition Corp. III was acquired by Paya, Inc., in a reverse merger transaction. FinTech Acquisition Corp. III does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination with one or more businesses or assets. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Lendbuzz develops an AI-based auto finance platform for people with a thin or no credit history. It helps consumers with a thin or no credit history obtain financing when purchasing a car. Powered by machine learning and proprietary algorithms, Lendbuzz is able to better assess the creditworthiness of consumers with limited credit history, who are underserved by traditional banks. By partnering with auto dealerships, Lendbuzz is able to offer consumers attractive financing solutions and dealerships are able to close additional business opportunities and serve a more diversified client base. The company was founded in 2015 and is headquartered in Boston, Massachusetts.
Faire is a two-sided marketplace and wholesale platform that helps retailers find and buy unique wholesale merchandise for their stores while helping brands and makers reach local retailers. Faire offers business owners a toolkit of simple tech, data insights, financial terms, and logistics solutions to support the future of local retail. Faire's net 60 payment terms and free returns take the risk out of the wholesale business so that local retailers and independent brands can compete with big-box and ecommerce giants. Faire is headquartered in San Francisco, California, United States, and Kitchener, Ontario, Canada.
Latch is an operating system of software, products, and services. They were designed to help owners, residents, and third parties like guests, couriers, and service providers seamlessly experience the modern building.
Mortgages help borrowers become homeowners. Yet, closing a mortgage is a complex transaction that requires multiple participants, processes, and technology. Borrowers are thrown into an intricate, stressful process instead of feeling excited and confident about this meaningful investment. And the teams responsible for delivering the loan should feel empowered to close efficiently. To improve both borrower experience and business outcomes, lenders and title companies operating at the center of the closing need the right tools—which is why we built Snapdocs. Snapdocs is the leading digital closing solution connecting the people, processes, and technologies that power mortgage closings. Our platform automates every interaction between lenders and title companies across the mortgage closing process, from pre-closing through the sale of the loan. With our patented AI technology, hands-on customer service, and extensive settlement and notary networks, all mortgage participants enjoy accurate, smooth, and secure closings. This approach gives customers a competitive advantage by saving them time and money. Snapdocs makes mortgage a snap. For more information, please visit www.snapdocs.com.
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
Urban provides a marketplace for freelance labor. It offers a variety of home services to consumers, including beauty treatments, haircuts, deep cleaning, plumbing, carpentry, and appliance repairs. The platform helps customers book reliable home services and it aims to help millions of service professionals across the world to deliver services at home. The company partners with tens of thousands of service professionals, helping them with training, credit, product procurement, insurance, and technology.
Scale AI develops a data-oriented platform that provides training and validation data for artificial intelligence applications. The company's LiDAR, video, and image annotation APIs allow self-driving, drone, and robotics teams at companies like Lyft, OpenAI, Zoox, Pinterest, and Airbnb to focus on building differentiated models vs. labeling data.
Patreon is a membership platform that makes it easy for artists and creators to get paid. It operates a platform that enables content creators, as well as artists, to be able to fund their work. It's Patreon.com, a communications platform, enables connection between users and makes various accessible content, including videos, photographs, images, artwork, graphics, audio clips, comments, data, text, software, scripts, projects, other material and information, and associated trademarks and copyrightable works. Patrons pledge to support artists and creators on a recurring basis for each work created, empowering a new generation of creators the ability to make a living off of their passions.
Swiggy is an on-demand food delivery platform that brings food from neighborhood restaurants directly to customers' doors. The company's food delivery platform lists local restaurants and menu lists on an app for users to order from and track the delivery of its delivery executives, enabling users to order food with speed and convenience. Its service is used to pick up and drop off a diverse array of items, including laundry and document or parcel deliveries to business clients and retail customers.
Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.
Paidy is a software platform that allows consumers to buy online without a credit card or pre-registration. It is optimized for mobile and instant-checkout, Paidy allows consumers to buy online and does not require a credit card or pre-registration. Paidy's payment service allows users to make purchases online, and then pay for them each month in a consolidated bill. The company uses proprietary technology to score creditworthiness, underwrite transactions and guarantee payment to merchants. Since many Japanese consumers prefer not to use credit cards for online payments, Paidy’s service can help vendors increase their conversion rates, average order values and repeat purchases.
Arrival Limited is a technology company based in London that specializes in manufacturing electric vehicles. Founded in 2015, the company focuses on developing software, materials, components, and scalable skateboard platforms, which serve as the foundation for its electric vehicles. Arrival's innovative approach includes the use of micro-factories, enabling efficient production and adaptation to various mobility ecosystems while minimizing capital expenditure. This model allows the company to produce zero-emission vehicles tailored to the needs of urban environments and aims to enhance public transportation through intelligent design. In addition to its headquarters in the United Kingdom, Arrival operates offices in Germany, the Netherlands, Israel, Russia, and the United States.
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.
Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical needs and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins, and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, they are developing a series of potentially first-in-class therapeutics.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases.
Private Equity Round in 2021
PPRO is a fintech company that provides digital payments infrastructure to businesses and banks so that they can scale their checkout, acquiring, and risk services through one connection. Payment platforms, acquirers, and merchants that plug into PPRO’s infrastructure can access payment methods, fraud screening tools, and other essential products from multiple providers. Every product can be deployed and controlled with clicks, not code. With the company's orchestration layer directing process flows and data like clockwork, PPRO’s partners can rest easy knowing they’re delivering seamless end-to-end services to their customers. Citi, PayPal, and Stripe are just some of the names that depend on PPRO to accelerate their roadmaps, boost their conversions, and eliminate the complexities of digital payments.
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
Billtrust is a provider of cloud-based software and integrated payment processing solutions that simplify and automate B2B commerce. Accounts receivable (AR) is broken and relies on conventional processes that are outdated, inefficient, manual and largely paper-based. Billtrust is at the forefront of the digital transformation of AR, providing mission-critical solutions that span credit decisioning and monitoring, online ordering, invoicing, cash application and collections. Billtrust's solutions integrate with a number of ecosystem players, including financial institutions, enterprise resource planning (ERP) systems, and accounts payable (AP) software platforms, to help customers recognize revenue more quickly and efficiently. Customers use Billtrust's platform to transition from expensive paper invoicing and check acceptance to efficient electronic billing and payments, which accelerates revenue capture, generates cost savings, and provides a better user experience.
Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases. This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existing vaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today. The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform.
Porch Group is a vertical software company that focuses on making the home simple by providing software and services to companies. They provide a moving concierge service to homebuyers, helping them save time and make better decisions on critical services, including insurance, moving, security, TV, internet, home repair and improvement, and more.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
Current is a leading U.S. challenger bank built to meet the needs of people with unique lives who have been overlooked by the traditional banking industry. Our proprietary Current Core technology allows us to provide premium banking services for everyone, regardless of age or income, and improve the financial outcomes of our members without overdraft fees, minimum balance requirements, or hidden fees. We give members up to two days faster direct deposit paychecks, free overdrafts up to $100 with Overdrive™ , points on purchases redeemable for cash back, access to 55,000 free ATMs worldwide as well as 24/7 member support 365 days a year.
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.
Scopely is an interactive entertainment and video game company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Stumble Guys”, and “Yahtzee With Buddies,” among others. Scopely creates, publishes, and live-operates immersive games that empower a directed-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami™ that supports one of the diversified portfolios in the mobile games industry. Recognized multiple times as Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has operations in more than a dozen markets across Asia-Pacific, including Bangalore and Shanghai, among others; EMEA, including Barcelona and Dublin, among others; and North America, including Boulder, Colorado, and Culver City, California, among others, with additional game studio partners across four continents.
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology. It engages in treating patients with the most difficult-to-treat cancers for which conventional therapies have failed.
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development. Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies.
Attentive is the leader in conversational commerce, reinventing business to consumer communication. The SMS-first software platform helps everyone from entrepreneurs to enterprises strengthen relationships with their consumers in a new way.
Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.
Affirm is a financial technology services company providing installment loans to consumers at the point of sale. The company was founded with the goal to create honest financial products and services that empower consumers and improve lives. It aims to revolutionize the banking industry to be more accountable and accessible to consumers. Today, Affirm provides shoppers with an alternative to traditional credit cards at the point of sale, giving them the flexibility to buy now and make simple monthly payments for their purchases. Unlike payment options that have compounding interest and unexpected costs, Affirm shows customers upfront exactly what they’ll pay each month—with no hidden fees and no surprises. Affirm partners with over 2,000 merchants to give shoppers the option to pay with Affirm at checkout, including well-known brands across retail, including home furnishings, travel, personal fitness, electronics, apparel and beauty, and more.
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
Skillz is the mobile games platform on a mission to bring out the best in everyone through fun and fair competition. The Skillz platform helps developers create multi-million dollar franchises by enabling social competition in their games. Leveraging its patented technology, Skillz hosts billions of casual mobile gaming tournaments for millions of players worldwide. As the pioneer of skill-based competition for mobile gaming, Skillz has earned recognition with Parity.Org’s 2022 Best Companies for Women to Advance, Deloitte 2022 Tech Fast 500 and one of Fast Company’s Most Innovative Companies in 2023.
Patreon is a membership platform that makes it easy for artists and creators to get paid. It operates a platform that enables content creators, as well as artists, to be able to fund their work. It's Patreon.com, a communications platform, enables connection between users and makes various accessible content, including videos, photographs, images, artwork, graphics, audio clips, comments, data, text, software, scripts, projects, other material and information, and associated trademarks and copyrightable works. Patrons pledge to support artists and creators on a recurring basis for each work created, empowering a new generation of creators the ability to make a living off of their passions.
Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. The company was founded in 2012 and is based in Redwood City, California.
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development. Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies.
Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease. It is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Its Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. The company was founded in 2016 and is based in Cambridge, Massachusetts.
Freeline is a clinical biotechnology company that develops transformative adeno-associated virus-vector-mediated systemic gene therapies. They use a designed AAV vector and capsid along with novel promoters and transgenes to deliver a functional copy of a therapeutic gene into human liver cells to express a functional level of the missing or dysfunctional protein into the patient’s bloodstream. Their development programs including clinical trials focus on developing products.
Prove is a smartphone-based identity verification startup that specializes in providing phone-centric and API marketplace solutions. Its phone-centric solutions enable its customers to acquire new consumers and engage with their existing consumers by removing friction while bolstering security and enhancing consumer privacy and consumer choice.
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.
Juspay is a developer of an online platform designed to be used for mobile-based payments. The company's online platform is a SaaS layer on top of payment gateways to simplify integration, improve robustness and ease the management of diverse and rapidly evolving payment options, enabling users to make electronic transactions securely and efficiently.
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation.
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.
Swiggy is an on-demand food delivery platform that brings food from neighborhood restaurants directly to customers' doors. The company's food delivery platform lists local restaurants and menu lists on an app for users to order from and track the delivery of its delivery executives, enabling users to order food with speed and convenience. Its service is used to pick up and drop off a diverse array of items, including laundry and document or parcel deliveries to business clients and retail customers.
Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers. FORMA’s approach to accessing such high value drug targets, many of which pose significant challenges to conventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling screening, discovery and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. FORMA is building a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms. FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.